Residual Inflammatory Risk-Guided colcHicine in Elderly Trial (RIGHT)

Inclusion Criteria: Aged 60-80 years old Baseline plasma hs-CRP≥2 mg/L Hospitalized patients with coronary artery disease with multi-vessel lesions (multi-vessel lesions are defined as at least 2 major epicardial coronary arteries with ≥50% stenosis in their main branch diameter confirmed by coronary CT or coronary angiography, with or without left main artery disease) Patients with myocardial ischemia-related symptoms or objective evidence are successfully treated with PCI, and the condition is relatively stable Received standard drug therapies based on their condition at baseline (including antiplatelet, lipid-lowering, blood pressure control, blood glucose control, and other treatments recommended by guidelines) Subjects or legal representatives have signed informed consent. Exclusion Criteria: Patients who have acute myocardial infarction within 30 days Patients who have taken colchicine and have a clear history of allergy or intolerance Patients with renal insufficiency, eGFR <30 ml/min/1.73 m^2 (calculated by MDRD formula) or blood creatinine levels exceeding 2 times the upper normal limit Patients with cirrhosis, chronic active hepatitis, liver function impairment (alanine aminotransferase exceeding 3 times the upper normal limit or total bilirubin exceeding 2 times the upper normal limit) or cholestasis Patients with a known history of hypomyelodysplasia Patients with heart failure (NYHA Class III-IV) or severe valvular disease Patients with concomitant neoplastic or cancer disease Patients with chronic obstructive pulmonary disease or other chronic pulmonary disease Patients with poorly controlled disease, such as current cardiogenic shock, hemodynamic instability, heart failure (NYHA Class III-IV), left ventricular ejection fraction less than 35%, recent stroke (within the past 3 months), or any other condition in which the investigator believes that participation in this study puts the patient at risk Patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea Patients with hemoglobin less than 115 g/L, white blood cell count less than 4.0*10^9/L, or platelet count less than 110*10^9/L Patients are currently using or plan to begin chronic systemic steroid therapy (oral or intravenous) during the study period (topical or inhaled steroids are allowed) Patients with acute inflammation or viral infection Female patients who are currently pregnant, planning to become pregnant, or breastfeeding